Total Payments
$6,904
2024 Payments
$2,444
Companies
31
Transactions
392
Medicare Patients
1,099
Medicare Billing
$112,174
Payment Breakdown by Category
Food & Beverage$6,758 (97.9%)
Education$145.92 (2.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $6,758 | 387 | 97.9% |
| Education | $145.92 | 5 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $944.20 | 35 | $0 (2024) |
| ABBVIE INC. | $767.00 | 66 | $0 (2024) |
| Novo Nordisk Inc | $686.47 | 42 | $0 (2024) |
| Amgen Inc. | $551.13 | 22 | $0 (2024) |
| PFIZER INC. | $528.34 | 22 | $0 (2024) |
| Lilly USA, LLC | $524.41 | 43 | $0 (2024) |
| Astellas Pharma US Inc | $436.60 | 24 | $0 (2024) |
| Merck Sharp & Dohme LLC | $391.74 | 22 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $376.88 | 20 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $265.39 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,444 | 127 | Amgen Inc. ($390.35) |
| 2023 | $2,392 | 136 | AstraZeneca Pharmaceuticals LP ($349.53) |
| 2022 | $1,705 | 112 | Novo Nordisk Inc ($312.17) |
| 2021 | $342.95 | 16 | AstraZeneca Pharmaceuticals LP ($159.70) |
| 2018 | $19.56 | 1 | Merck Sharp & Dohme Corporation ($19.56) |
All Payment Transactions
392 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.48 | General |
| Category: Gastroenterology | ||||||
| 12/17/2024 | Axsome Therapeutics, Inc. | Sunosi (Drug) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: Neurology | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $10.52 | General |
| Category: Inflammation | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: Biological | ||||||
| 11/25/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Endocrinology | ||||||
| 11/21/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: Inflammation | ||||||
| 11/20/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $22.30 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Gastroenterology | ||||||
| 11/18/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $31.11 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.50 | General |
| Category: DIABETES | ||||||
| 11/14/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/14/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $5.74 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: Biological | ||||||
| 11/12/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: ANTIBIOTIC | ||||||
| 11/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $1.41 | General |
| Category: NEUROSCIENCE | ||||||
| 10/30/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $9.58 | General |
| Category: Inflammation | ||||||
| 10/29/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.49 | General |
| Category: Diabetes | ||||||
| 10/29/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: RESPIRATORY | ||||||
| 10/21/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Obesity | ||||||
| 10/16/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.28 | General |
| Category: PSYCHIATRY | ||||||
| 10/09/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: Biological | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.38 | General |
| Category: Gastroenterology | ||||||
| 10/03/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $20.02 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 599 | 1,974 | $140,610 | $62,541 |
| 2022 | 11 | 484 | 1,619 | $110,621 | $47,992 |
| 2021 | 1 | 16 | 18 | $3,150 | $1,641 |
Total Patients
1,099
Total Services
3,611
Medicare Billing
$112,174
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 196 | 526 | $92,050 | $41,834 | 45.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 74 | $17,390 | $8,882 | 51.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 45 | 45 | $6,750 | $5,283 | 78.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 19 | $2,185 | $1,190 | 54.5% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2023 | 29 | 29 | $1,015 | $967.67 | 95.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 96 | $3,325 | $869.55 | 26.2% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 19 | 20 | $2,000 | $811.00 | 40.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 25 | 25 | $875.00 | $737.75 | 84.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $2,970 | $723.72 | 24.4% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 13 | 26 | $1,040 | $421.72 | 40.6% |
| 20552 | Injection of trigger points, 1-2 muscles | Office | 2023 | 11 | 11 | $1,540 | $383.40 | 24.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 15 | 15 | $1,275 | $156.45 | 12.3% |
| 81002 | Urinalysis, manual test | Office | 2023 | 19 | 26 | $520.00 | $88.66 | 17.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 23 | 112 | $1,120 | $76.26 | 6.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 53 | 787 | $2,755 | $64.09 | 2.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 26 | 152 | $3,800 | $50.97 | 1.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 149 | 406 | $71,050 | $32,745 | 46.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 29 | 40 | $9,400 | $4,776 | 50.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 55 | 65 | $7,475 | $2,955 | 39.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 23 | 23 | $3,450 | $2,751 | 79.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 15 | 16 | $4,320 | $1,151 | 26.7% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 22 | 22 | $3,300 | $1,122 | 34.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 58 | 99 | $3,465 | $884.89 | 25.5% |
| 90674 | Influenza vaccine, quadrivalent derived from cell cultures, preservative and antibiotic free | Office | 2022 | 24 | 25 | $875.00 | $789.06 | 90.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 24 | 25 | $875.00 | $710.08 | 81.2% |
About Dr. Eric Cline, MD
Dr. Eric Cline, MD is a Family Medicine healthcare provider based in Nacogdoches, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2018. The National Provider Identifier (NPI) number assigned to this provider is 1073004719.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Cline, MD has received a total of $6,904 in payments from pharmaceutical and medical device companies, with $2,444 received in 2024. These payments were reported across 392 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($6,758).
As a Medicare-enrolled provider, Cline has provided services to 1,099 Medicare beneficiaries, totaling 3,611 services with total Medicare billing of $112,174. Data is available for 3 years (2021–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Nacogdoches, TX
- Active Since 05/29/2018
- Last Updated 10/08/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1073004719
Products in Payments
- BREZTRI (Drug) $504.58
- FARXIGA (Drug) $384.99
- Kerendia (Drug) $376.88
- Ozempic (Drug) $344.94
- VRAYLAR (Drug) $329.41
- MOUNJARO (Drug) $325.46
- Veozah (Drug) $308.31
- Repatha (Biological) $299.04
- CAPLYTA (Drug) $283.58
- REXULTI (Drug) $265.39
- UBRELVY (Drug) $247.21
- PREVNAR 20 (Biological) $218.01
- XIFAXAN (Drug) $210.07
- BELSOMRA (Drug) $206.10
- JARDIANCE (Drug) $185.56
- Dexcom G6 Transmitter (Medical Supply) $183.47
- Otezla (Drug) $171.65
- ELIQUIS (Drug) $169.16
- Wegovy (Drug) $167.72
- Rybelsus (Drug) $144.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Nacogdoches
Dr. Mark Cline, M.d, M.D
Family Medicine — Payments: $12,124
Family Medicine $12,124
Dr. Kelley Moon, M.d, M.D
Family Medicine — Payments: $9,736
Family Medicine $9,736
Rachel Cline
Family Medicine — Payments: $6,628
Family Medicine $6,628
Dr. Philip Labarbera, M.d, M.D
Family Medicine — Payments: $5,195
Family Medicine $5,195
Bryan Davis, M.d, M.D
Family Medicine — Payments: $2,951
Family Medicine $2,951
Dr. Wilburn Furniss, M.d, M.D
Family Medicine — Payments: $2,314
Family Medicine $2,314